@article {Tyrere000582, author = {Peter Tyrer and Helen Tyrer and Richard Morriss and Michael Crawford and Sylvia Cooper and Min Yang and Boliang Guo and Roger T Mulder and Samuel Kemp and Barbara Barrett}, title = {Clinical and cost-effectiveness of adapted cognitive behaviour therapy for non-cardiac chest pain: a multicentre, randomised controlled trial}, volume = {4}, number = {1}, elocation-id = {e000582}, year = {2017}, doi = {10.1136/openhrt-2016-000582}, publisher = {Archives of Disease in childhood}, abstract = {Objective To investigate the cost-effectiveness of a modified form of cognitive behavioural therapy (CBT) for recurrent non-cardiac chest pain.Methods We tested the effectiveness and cost-effectiveness of a modified form of CBT for chest pain (CBT-CP)(4{\textendash}10 sessions) in patients who attended cardiology clinics or emergency medical services repeatedly. Patients were randomised using a remote web-based system to CBT-CP or to standard care in the clinic. Assessments were made at baseline and at 6 months and 12 months. The primary outcome was the change in the Health Anxiety Inventory Score at 6 months. Other clinical measures, social functioning, quality of life and costs of services were also recorded.Results Sixty-eight patients were randomised with low attrition rates at 6 months and 12 months with 81\% of all possible assessments completed at 6 months and 12 months. Although there were no significant group differences between any of the outcome measures at either 6 months or 12 months, patients receiving CBT-CP had between two and three times fewer hospital bed days, outpatient appointments, and A\&E attendances than those allocated to standard care and total costs per patient were {\textsterling}1496.49 lower, though the differences in costs were not significant. There was a small non-significant gain in quality adjusted life years in those allocated to CBT-CP compared with standard care (0.76 vs 0.74).Conclusions It is concluded that CBT-CP in the context of current hospital structures is not a viable treatment, but is worthy of further research as a potentially cost-effective treatment for non-cardiac chest pain.Trial registration number ISRCTN 14711101.}, URL = {https://openheart.bmj.com/content/4/1/e000582}, eprint = {https://openheart.bmj.com/content/4/1/e000582.full.pdf}, journal = {Open Heart} }